Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). New England Journal of Medicine.
Summary
The SURMOUNT-1 trial, which established tirzepatide as a weight-loss treatment. Adults with obesity, or with overweight plus a weight-related condition but not diabetes, were randomised to one of three tirzepatide levels or placebo, given by weekly injection for 72 weeks. Mean starting weight was about 105 kg. Both co-primary endpoints, percentage weight change and the proportion losing at least 5 percent, favoured tirzepatide across all three treatment groups. The trial was funded by the manufacturer.